Status:

COMPLETED

Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir

Lead Sponsor:

Hospitales Universitarios Virgen del Rocío

Collaborating Sponsors:

Bristol-Myers Squibb

Conditions:

Hepatitis C, Chronic

HIV Infection

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

Hypothesis: the Telaprevir(TVR) plasma levels (750 mg q8h or 1125 mg/12h )will not be affected when co-administered with un-boosted Atazanavir (ATV) 200 mg q12h plus two analogues (NRTIs) in HCV/HIV-c...

Detailed Description

Objectives 1. Primary Outcome Measures: evaluate the changes in the plasma pharmacokinetic parameters (Cmax, Cmin, AUC, t 1/2, and Cl) of Telaprevir (TVR) administered at 750 mg/8h together with un-b...

Eligibility Criteria

Inclusion

  • Patients over 18 years old co-infected with HIV and genotype 1 HCV under treatment with pegylated α-interferon, Ribavirin and Telaprevir according to the recommendations of the Spanish Agency of Medicines and Health Products.
  • Informed consent of the patient.

Exclusion

  • The usual exclusion criteria in clinical practice to start the treatment with these drugs (pegylated α-interferon, Ribavirin, Telaprevir and atazanavir) according to the Spanish and international recommendations (Spanish Agency of Medicines and Health Products,European Association for the Study of the Liver Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011. Consensus Document of Gesida/Spanish Plan on Aids regarding the antiretroviral treatment in adults infected with the human immunodeficiency virus \[Updated January 2012\]).
  • Concomitant use of drugs or medicinal products that could alter the pharmacokinetics of TVR or ATV.
  • Medical records suggesting malabsorption or presence of diarrhea (\>3 depositions/day) that could interfere with the absorption of the studied drugs.

Key Trial Info

Start Date :

December 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2013

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT01818856

Start Date

December 1 2012

End Date

April 1 2013

Last Update

April 22 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital Universitario Virgen del Rocio

Seville, Seville, Spain, 41013